The test produces a clear and customized report that indicates the estimated risk of developing breast cancer within the next 5 years. MammoRisk® is an AI-based tool that predicts the likelihood of developing breast cancer for women over the age of 40 who have never had breast cancer. This solution is developed by the French company Predilife. MammoRisk® is a unique tool that uses the latest scien
tific knowledge regarding the main risk factors (clinical data, imaging, and genetic data) to produce personalized monitoring program tailored to each patient women according to her risk. Predilife is a leading French company, develops predictive tests for the medicine of the future: Predictive, Preventive, Personalized, and Participatory (4Ps). Mena Medical Development - MMD is the regional representative of Predilife in the Middle East and North Africa (MENA) region , and other international markets such as South Africa. Launched in Lebanon in 2010, MMD was founded with the aim of providing state-of-the-art medical and biomedical solutions in the MENA region. Today, MMD Group, operates from 3 locations: Lebanon, Turkey, and UAE, with bigger ambitions for a brighter future.
